Author:
Edahiro Yoko,Ochiai Tomonori,Hashimoto Yoshinori,Morishita Soji,Shirane Shuichi,Inano Tadaaki,Furuya Chiho,Koike Michiaki,Noguchi Masaaki,Usuki Kensuke,Shiratsuchi Motoaki,Nakajima Kei,Ohtsuka Eiichi,Tanaka Hiroaki,Kawata Eri,Nakamae Mika,Ueda Yasunori,Aota Yasuo,Sugita Yasumasa,Ohara Shin,Yamasaki Satoshi,Asagoe Kohsuke,Yoshida Shuro,Yamanouchi Jun,Suzuki Sayaka,Kondo Toshinori,Kanisawa Yuji,Toyama Kohtaro,Omura Hiromi,Mizuchi Daisuke,Sakamaki Sumio,Ando Miki,Komatsu Norio
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues revised. 4th ed. Lyon, France: IARC; 2017.
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
3. Remacha AF, Nomdedéu JF, Puget G, Estivill C, Sarda MP, Canals C, et al. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica. 2006;91(5):719–20.
4. Gattermann N, Billiet J, Kronenwett R, Zipperer E, Germing U, Nollet F, et al. High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood. 2007;109(3):1334–5.
5. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012;119(2):569–72.